;PMID: 9143352
;source_file_902.mrg
;Release 0.9 of PennBioIE
;Funded by NSF ITR EIA-0205448

;0)section:[e:0..46] = [t:0..46]
;1)sentence:[e:52..124] = [t:52..124]
;2)section:[e:128..160] = [t:128..159]
;3)section:[e:164..288] = [t:164..288]
;4)sentence:[e:292..470] = [t:292..470]
;5)sentence:[e:471..649] = [t:471..649]
;6)sentence:[e:650..768] = [t:650..768]
;7)sentence:[e:770..1043] = [t:770..1043]
;8)sentence:[e:1044..1624] = [t:1044..1624]
;9)sentence:[e:1625..1790] = [t:1625..1790]
;10)sentence:[e:1791..2088] = [t:1791..2088]
;11)sentence:[e:2090..2240] = [t:2090..2240]
;12)sentence:[e:2241..2454] = [t:2241..2454]
;13)sentence:[e:2455..2632] = [t:2455..2632]
;14)sentence:[e:2633..2722] = [t:2633..2722]
;15)sentence:[e:2723..2921] = [t:2723..2921]
;16)sentence:[e:2922..3050] = [t:2922..3050]
;17)section:[e:3054..3098] = [t:3054..3097]
;Sentence Matching Errors
;ERROR_Section end mismatch[e:128..160][t:128..159]
;ERROR_Section end mismatch[e:3054..3098][t:3054..3097]
;Token/POS Errors
;ERROR_Token in entity file but not tree[38..39] )
;ERROR_Token in entity file but not tree[39..40] :
;ERROR_Token in entity file but not tree[159..160] .
;ERROR_Token in entity file but not tree[3097..3098] ]
;ERROR_Token in tree file but not entity[38..40] ):

;section 0 Span:0..46
;Arch Biochem Biophys. 1997 May 1;341(1):47-61.
(SEC
  (FRAG (NNP:[0..4] Arch) (NNP:[5..12] Biochem) (NNP:[13..20] Biophys)
        (.:[20..21] .) (CD:[22..26] 1997) (NNP:[27..30] May) (CD:[31..32] 1)
        (::[32..33] ;) (CD:[33..36] 341) (-LRB-:[36..37] -LRB-) (CD:[37..38] 1)
        (-RRB-:[38..40] -RRB-:) (CD:[40..42] 47) (::[42..43] -) (CD:[43..45] 61)
        (.:[45..46] .)))

;sentence 1 Span:52..124
;Inhibition of coumarin 7-hydroxylase activity in human liver microsomes.
;[66..88]:cyp450:"coumarin 7-hydroxylase"
(SENT
  (NP-HLN
    (NP (NN:[52..62] Inhibition))
    (PP (IN:[63..65] of)
      (NP
         (NN:[66..74] coumarin) (NN:[75..88] 7-hydroxylase)
        (NN:[89..97] activity)))
    (PP-LOC (IN:[98..100] in)
      (NP (JJ:[101..106] human) (NN:[107..112] liver)
          (NNS:[113..123] microsomes)))
    (.:[123..124] .)))

;section 2 Span:128..159
;Draper AJ, Madan A, Parkinson A
(SEC
  (FRAG (NNP:[128..134] Draper) (NNP:[135..137] AJ) (,:[137..138] ,)
        (NNP:[139..144] Madan) (NNP:[145..146] A) (,:[146..147] ,)
        (NNP:[148..157] Parkinson) (NN:[158..159] A)))

(ORPH .)

;section 3 Span:164..288
;Department of Pharmacology, Toxicology, and Therapeutics, University of
;Kansas  Medical Center, Kansas City 66160-7417, USA.
(SEC
  (FRAG (NNP:[164..174] Department) (IN:[175..177] of)
        (NNP:[178..190] Pharmacology) (,:[190..191] ,)
        (NNP:[192..202] Toxicology) (,:[202..203] ,) (CC:[204..207] and)
        (NNP:[208..220] Therapeutics) (,:[220..221] ,)
        (NNP:[222..232] University) (IN:[233..235] of) (NNP:[236..242] Kansas)
        (NNP:[244..251] Medical) (NNP:[252..258] Center) (,:[258..259] ,)
        (NNP:[260..266] Kansas) (NNP:[267..271] City) (CD:[272..277] 66160)
        (::[277..278] -) (CD:[278..282] 7417) (,:[282..283] ,)
        (NNP:[284..287] USA) (.:[287..288] .)))
;ERROR_Orphan Text from Tree File[159..164] .

;sentence 4 Span:292..470
;Nine organic solvents and 47 commonly used P450 substrates and inhibitors
;were  examined for their effects on coumarin 7-hydroxylase (CYP2A6) activity
;in human  liver microsomes.
;[297..313]:substance:"organic solvents"
;[335..339]:cyp450:"P450"
;[340..350]:substance:"substrates"
;[355..365]:substance:"inhibitors"
;[402..424]:cyp450:"coumarin 7-hydroxylase"
;[426..432]:cyp450:"CYP2A6"
(SENT
  (S
    (NP-SBJ-3
      (NP (CD:[292..296] Nine)
         (JJ:[297..304] organic) (NNS:[305..313] solvents))
      (CC:[314..317] and)
      (NP (CD:[318..320] 47)
        (NML
          (NP
            (ADJP-1 (RB:[321..329] commonly) (VBN:[330..334] used))
            (NML-2 (NN:[335..339] P450))
            (NNS:[340..350] substrates))
          (CC:[351..354] and)
          (NP
            (ADJP-1 (-NONE-:[354..354] *P*))
            (NML-2 (-NONE-:[354..354] *P*))
            (NNS:[355..365] inhibitors)))))
    (VP (VBD:[366..370] were)
      (VP (VBN:[372..380] examined)
        (NP-3 (-NONE-:[380..380] *))
        (PP (IN:[381..384] for)
          (NP
            (NP (PRP$:[385..390] their) (NNS:[391..398] effects))
            (PP (IN:[399..401] on)
              (NP
                (NML
                  (NML (NN:[402..410] coumarin) (NN:[411..424] 7-hydroxylase))
                  (NML (-LRB-:[425..426] -LRB-) (NN:[426..432] CYP2A6)
                       (-RRB-:[432..433] -RRB-)))
                (NN:[434..442] activity)))
            (PP-LOC (IN:[443..445] in)
              (NP (JJ:[446..451] human) (NN:[453..458] liver)
                  (NNS:[459..469] microsomes)))))))
    (.:[469..470] .)))

;sentence 5 Span:471..649
;Of the nine organic solvents examined (final concentration 1%,  v/v), only
;methanol did not inhibit the 7-hydroxylation of coumarin (0.5 to 50  microM)
;by human liver microsomes.
;[483..499]:substance:"organic solvents"
;[530..532]:quantitative-value:"1%"
;[535..538]:quantitative-units:"v/v"
;[546..554]:substance:"methanol"
;[594..602]:substance:"coumarin"
;[604..613]:quantitative-value:"0.5 to 50"
;[615..621]:quantitative-units:"microM"
(SENT
  (S
    (PP-TPC-1 (IN:[471..473] Of)
      (NP
        (NP (DT:[474..477] the) (CD:[478..482] nine)
           (JJ:[483..490] organic) (NNS:[491..499] solvents))
        (VP (VBN:[500..508] examined)
          (NP (-NONE-:[508..508] *)))
        (PRN (-LRB-:[509..510] -LRB-)
          (FRAG
            (S
              (NP-SBJ (JJ:[510..515] final) (NN:[516..529] concentration))
              (NP-PRD (CD:[530..531] 1) (NN:[531..532] %)))
            (,:[532..533] ,)
            (NP
              (NP (NN:[535..536] v))
              (PP (SYM:[536..537] /)
                (NP (NN:[537..538] v)))))
          (-RRB-:[538..539] -RRB-))))
    (,:[539..540] ,)
    (NP-SBJ
      (NP (RB:[541..545] only) (NN:[546..554] methanol))
      (PP-1 (-NONE-:[554..554] *T*)))
    (VP (VBD:[555..558] did) (RB:[559..562] not)
      (VP (VB:[563..570] inhibit)
        (NP
          (NP (DT:[571..574] the) (CD:[575..576] 7) (HYPH:[576..577] -)
              (NN:[577..590] hydroxylation))
          (PP (IN:[591..593] of)
            (NP (NN:[594..602] coumarin)))
          (PRN (-LRB-:[603..604] -LRB-)
            (NP
              (QP (CD:[604..607] 0.5) (TO:[608..610] to) (CD:[611..613] 50))
              (NN:[615..621] microM))
            (-RRB-:[621..622] -RRB-))
          (PP (IN:[623..625] by)
            (NP (JJ:[626..631] human) (NN:[632..637] liver)
                (NNS:[638..648] microsomes))))))
    (.:[648..649] .)))

;sentence 6 Span:650..768
;Dioxane and tetra-hydrofuran, which are  structurally related to coumarin,
;were the most inhibitory solvents examined.
;[650..657]:substance:"Dioxane"
;[662..678]:substance:"tetra-hydrofuran"
;[715..723]:substance:"coumarin"
;[750..758]:substance:"solvents"
(SENT
  (S
    (NP-SBJ
      (NP (NN:[650..657] Dioxane) (CC:[658..661] and)
          (NN:[662..678] tetra-hydrofuran))
      (,:[678..679] ,)
      (SBAR
        (WHNP-1 (WDT:[680..685] which))
        (S
          (NP-SBJ-1 (-NONE-:[685..685] *T*))
          (VP (VBP:[686..689] are)
            (ADVP (RB:[691..703] structurally))
            (VP (JJ:[704..711] related)
              (NP-1 (-NONE-:[711..711] *))
              (PP-CLR (TO:[712..714] to)
                (NP (NN:[715..723] coumarin))))))))
    (,:[723..724] ,)
    (VP (VBD:[725..729] were)
      (NP-PRD
        (NP (DT:[730..733] the)
          (ADJP (RBS:[734..738] most) (JJ:[739..749] inhibitory))
          (NNS:[750..758] solvents))
        (VP (VBN:[759..767] examined)
          (NP (-NONE-:[767..767] *)))))
    (.:[767..768] .)))

;sentence 7 Span:770..1043
;Although the rates of coumarin 7-hydroxylation varied enormously among nine 
;samples of human liver microsomes and cDNA-expressed CYP2A6 (Vmax = 179 to
;2470  pmol/ mg protein/min), the Km for coumarin 7-hydroxylation was fairly
;constant  (ranging from 0.50 to 0.70 microM).
;[792..800]:substance:"coumarin"
;[885..889]:substance:"cDNA"
;[900..906]:cyp450:"CYP2A6"
;[908..912]:quantitative-name:"Vmax"
;[915..926]:quantitative-value:"179 to 2470"
;[928..948]:quantitative-units:"pmol/ mg protein/min"
;[955..957]:quantitative-name:"Km"
;[962..970]:substance:"coumarin"
;[1022..1034]:quantitative-value:"0.50 to 0.70"
;[1035..1041]:quantitative-units:"microM"
(SENT
  (S
    (SBAR-ADV (IN:[770..778] Although)
      (S
        (NP-SBJ
          (NP (DT:[779..782] the) (NNS:[783..788] rates))
          (PP (IN:[789..791] of)
            (NP
              (NML (NN:[792..800] coumarin) (CD:[801..802] 7))
              (HYPH:[802..803] -) (NN:[803..816] hydroxylation))))
        (VP (VBD:[817..823] varied)
          (ADVP (RB:[824..834] enormously))
          (PP (IN:[835..840] among)
            (NP
              (NP (CD:[841..845] nine) (NNS:[847..854] samples))
              (PP (IN:[855..857] of)
                (NP
                  (NP (JJ:[858..863] human) (NN:[864..869] liver)
                      (NNS:[870..880] microsomes))
                  (CC:[881..884] and)
                  (NP
                    (ADJP (NN:[885..889] cDNA) (HYPH:[889..890] -)
                          (VBN:[890..899] expressed))
                    (NN:[900..906] CYP2A6))))))
          (PRN (-LRB-:[907..908] -LRB-)
            (S
              (NP-SBJ (NN:[908..912] Vmax))
              (VP (SYM:[913..914] =)
                (NP
                  (NP
                    (QP (CD:[915..918] 179) (TO:[919..921] to)
                        (CD:[922..926] 2470))
                    (NN:[928..932] pmol))
                  (PP (SYM:[932..933] /)
                    (NP (NN:[934..936] mg) (NN:[937..944] protein)))
                  (PP (SYM:[944..945] /)
                    (NP (NN:[945..948] min))))))
            (-RRB-:[948..949] -RRB-)))))
    (,:[949..950] ,)
    (NP-SBJ
      (NP (DT:[951..954] the) (NN:[955..957] Km))
      (PP (IN:[958..961] for)
        (NP
          (NML (NN:[962..970] coumarin) (CD:[971..972] 7))
          (HYPH:[972..973] -) (NN:[973..986] hydroxylation))))
    (VP (VBD:[987..990] was)
      (ADJP-PRD (RB:[991..997] fairly) (JJ:[998..1006] constant)
        (PRN (-LRB-:[1008..1009] -LRB-)
          (VP (VBG:[1009..1016] ranging)
            (PP (IN:[1017..1021] from)
              (NP (CD:[1022..1026] 0.50)))
            (PP (TO:[1027..1029] to)
              (NP (CD:[1030..1034] 0.70) (NN:[1035..1041] microM))))
          (-RRB-:[1041..1042] -RRB-))))
    (.:[1042..1043] .)))

;sentence 8 Span:1044..1624
;The following chemicals caused little or no  inhibition of CYP2A6 as defined
;by a Ki > 200 microM: caffeine, chlorzoxazone,  cimetidine, dextromethorphan,
;diazepam, diclofenac, erythromycin,  ethinylestradiol, ethynyltestosterone,
;fluconazole, furafylline, furfural,  hexobarbital, itraconazole, mephenytoin,
;methimazole, metronidazole, naringenin,  naringin, nifedipine, norfloxacin,
;norgestrel, orphenadrine, quinidine,  papaverine, phenacetin, pyrimethamine,
;ranitidine, spironolactone,  sulfaphenazole, sulfinpyrazone, testosterone,
;tolbutamide, troleandomycin, and  warfarin.
;[1058..1067]:substance:"chemicals"
;[1103..1109]:cyp450:"CYP2A6"
;[1126..1128]:quantitative-name:"Ki"
;[1129..1134]:quantitative-value:"> 200"
;[1135..1141]:quantitative-units:"microM"
;[1143..1151]:substance:"caffeine"
;[1153..1166]:substance:"chlorzoxazone"
;[1169..1179]:substance:"cimetidine"
;[1181..1197]:substance:"dextromethorphan"
;[1199..1207]:substance:"diazepam"
;[1209..1219]:substance:"diclofenac"
;[1221..1233]:substance:"erythromycin"
;[1236..1252]:substance:"ethinylestradiol"
;[1254..1273]:substance:"ethynyltestosterone"
;[1275..1286]:substance:"fluconazole"
;[1288..1299]:substance:"furafylline"
;[1301..1309]:substance:"furfural"
;[1312..1324]:substance:"hexobarbital"
;[1326..1338]:substance:"itraconazole"
;[1340..1351]:substance:"mephenytoin"
;[1353..1364]:substance:"methimazole"
;[1366..1379]:substance:"metronidazole"
;[1381..1391]:substance:"naringenin"
;[1394..1402]:substance:"naringin"
;[1404..1414]:substance:"nifedipine"
;[1416..1427]:substance:"norfloxacin"
;[1429..1439]:substance:"norgestrel"
;[1441..1453]:substance:"orphenadrine"
;[1455..1464]:substance:"quinidine"
;[1467..1477]:substance:"papaverine"
;[1479..1489]:substance:"phenacetin"
;[1491..1504]:substance:"pyrimethamine"
;[1506..1516]:substance:"ranitidine"
;[1518..1532]:substance:"spironolactone"
;[1535..1549]:substance:"sulfaphenazole"
;[1551..1565]:substance:"sulfinpyrazone"
;[1567..1579]:substance:"testosterone"
;[1581..1592]:substance:"tolbutamide"
;[1594..1608]:substance:"troleandomycin"
;[1615..1623]:substance:"warfarin"
(SENT
  (S
    (NP-SBJ
      (NP (DT:[1044..1047] The) (JJ:[1048..1057] following)
          (NNS:[1058..1067] chemicals))
      (NP-2 (-NONE-:[1067..1067] *ICH*)))
    (VP (VBD:[1068..1074] caused)
      (NP
        (NP
          (NP
            (NP (JJ:[1075..1081] little)
              (NML-3 (-NONE-:[1081..1081] *P*)))
            (CC:[1082..1084] or)
            (NP (DT:[1085..1087] no)
              (NML-3 (NN:[1089..1099] inhibition))))
          (PP (IN:[1100..1102] of)
            (NP (NN:[1103..1109] CYP2A6))))
        (SBAR (IN:[1110..1112] as)
          (S
            (NP-SBJ-1 (-NONE-:[1112..1112] *))
            (VP (VBN:[1113..1120] defined)
              (NP-1 (-NONE-:[1120..1120] *))
              (PP (IN:[1121..1123] by)
                (NP-LGS
                  (NP (DT:[1124..1125] a) (NN:[1126..1128] Ki))
                  (VP (SYM:[1129..1130] >)
                    (NP (CD:[1131..1134] 200) (NN:[1135..1141] microM)))))))))
      (::[1141..1142] :)
      (NP-2 (NN:[1143..1151] caffeine) (,:[1151..1152] ,)
            (NN:[1153..1166] chlorzoxazone) (,:[1166..1167] ,)
            (NN:[1169..1179] cimetidine) (,:[1179..1180] ,)
            (NN:[1181..1197] dextromethorphan) (,:[1197..1198] ,)
            (NN:[1199..1207] diazepam) (,:[1207..1208] ,)
            (NN:[1209..1219] diclofenac) (,:[1219..1220] ,)
            (NN:[1221..1233] erythromycin) (,:[1233..1234] ,)
            (NN:[1236..1252] ethinylestradiol) (,:[1252..1253] ,)
            (NN:[1254..1273] ethynyltestosterone) (,:[1273..1274] ,)
            (NN:[1275..1286] fluconazole) (,:[1286..1287] ,)
            (NN:[1288..1299] furafylline) (,:[1299..1300] ,)
            (NN:[1301..1309] furfural) (,:[1309..1310] ,)
            (NN:[1312..1324] hexobarbital) (,:[1324..1325] ,)
            (NN:[1326..1338] itraconazole) (,:[1338..1339] ,)
            (NN:[1340..1351] mephenytoin) (,:[1351..1352] ,)
            (NN:[1353..1364] methimazole) (,:[1364..1365] ,)
            (NN:[1366..1379] metronidazole) (,:[1379..1380] ,)
            (NN:[1381..1391] naringenin) (,:[1391..1392] ,)
            (NN:[1394..1402] naringin) (,:[1402..1403] ,)
            (NN:[1404..1414] nifedipine) (,:[1414..1415] ,)
            (NN:[1416..1427] norfloxacin) (,:[1427..1428] ,)
            (NN:[1429..1439] norgestrel) (,:[1439..1440] ,)
            (NN:[1441..1453] orphenadrine) (,:[1453..1454] ,)
            (NN:[1455..1464] quinidine) (,:[1464..1465] ,)
            (NN:[1467..1477] papaverine) (,:[1477..1478] ,)
            (NN:[1479..1489] phenacetin) (,:[1489..1490] ,)
            (NN:[1491..1504] pyrimethamine) (,:[1504..1505] ,)
            (NN:[1506..1516] ranitidine) (,:[1516..1517] ,)
            (NN:[1518..1532] spironolactone) (,:[1532..1533] ,)
            (NN:[1535..1549] sulfaphenazole) (,:[1549..1550] ,)
            (NN:[1551..1565] sulfinpyrazone) (,:[1565..1566] ,)
            (NN:[1567..1579] testosterone) (,:[1579..1580] ,)
            (NN:[1581..1592] tolbutamide) (,:[1592..1593] ,)
            (NN:[1594..1608] troleandomycin) (,:[1608..1609] ,)
            (CC:[1610..1613] and) (NN:[1615..1623] warfarin)))
    (.:[1623..1624] .)))

;sentence 9 Span:1625..1790
;In other words, these chemicals, at a final concentration of 100  microM,
;failed to inhibit CYP2A6 when the concentration of coumarin was equal to  Km
;(0.50 microM).
;[1647..1656]:substance:"chemicals"
;[1686..1689]:quantitative-value:"100"
;[1691..1697]:quantitative-units:"microM"
;[1717..1723]:cyp450:"CYP2A6"
;[1750..1758]:substance:"coumarin"
;[1773..1775]:quantitative-name:"Km"
;[1777..1781]:quantitative-value:"0.50"
;[1782..1788]:quantitative-units:"microM"
(SENT
  (S
    (PP (IN:[1625..1627] In)
      (NP (JJ:[1628..1633] other) (NNS:[1634..1639] words)))
    (,:[1639..1640] ,)
    (NP-SBJ-1
      (NP (DT:[1641..1646] these) (NNS:[1647..1656] chemicals))
      (,:[1656..1657] ,)
      (PP (IN:[1658..1660] at)
        (NP
          (NP (DT:[1661..1662] a) (JJ:[1663..1668] final)
              (NN:[1669..1682] concentration))
          (PP (IN:[1683..1685] of)
            (NP (CD:[1686..1689] 100) (NN:[1691..1697] microM))))))
    (,:[1697..1698] ,)
    (VP (VBD:[1699..1705] failed)
      (S
        (NP-SBJ-1 (-NONE-:[1705..1705] *))
        (VP (TO:[1706..1708] to)
          (VP (VB:[1709..1716] inhibit)
            (NP (NN:[1717..1723] CYP2A6))
            (SBAR-ADV
              (WHADVP-2 (WRB:[1724..1728] when))
              (S
                (NP-SBJ
                  (NP (DT:[1729..1732] the) (NN:[1733..1746] concentration))
                  (PP (IN:[1747..1749] of)
                    (NP (NN:[1750..1758] coumarin))))
                (VP (VBD:[1759..1762] was)
                  (ADJP-PRD (JJ:[1763..1768] equal)
                    (PP (TO:[1769..1771] to)
                      (NP (NN:[1773..1775] Km)
                        (PRN (-LRB-:[1776..1777] -LRB-)
                          (NP (CD:[1777..1781] 0.50) (NN:[1782..1788] microM))
                          (-RRB-:[1788..1789] -RRB-)))))
                  (ADVP-TMP-2 (-NONE-:[1789..1789] *T*)))))))))
    (.:[1789..1790] .)))

;sentence 10 Span:1791..2088
;The following chemicals were classified as strong inhibitors  of CYP2A6
;(defined by Ki < 200 microM): clotrimazole, diethyldithiocarbamate, 
;ellipticine, ketoconazole, 8-methoxypsoralen, 4-methylpyrazole, metyrapone, 
;miconazole, alpha-naphthoflavone, nicotine, p-nitrophenol, and
;tranylcypromine.
;[1805..1814]:substance:"chemicals"
;[1841..1851]:substance:"inhibitors"
;[1856..1862]:cyp450:"CYP2A6"
;[1875..1877]:quantitative-name:"Ki"
;[1878..1883]:quantitative-value:"< 200"
;[1884..1890]:quantitative-units:"microM"
;[1893..1905]:substance:"clotrimazole"
;[1907..1929]:substance:"diethyldithiocarbamate"
;[1932..1943]:substance:"ellipticine"
;[1945..1957]:substance:"ketoconazole"
;[1959..1976]:substance:"8-methoxypsoralen"
;[1978..1994]:substance:"4-methylpyrazole"
;[1996..2006]:substance:"metyrapone"
;[2009..2019]:substance:"miconazole"
;[2021..2041]:substance:"alpha-naphthoflavone"
;[2043..2051]:substance:"nicotine"
;[2053..2066]:substance:"p-nitrophenol"
;[2072..2087]:substance:"tranylcypromine"
(SENT
  (S
    (NP-SBJ-1
      (NP (DT:[1791..1794] The) (JJ:[1795..1804] following)
          (NNS:[1805..1814] chemicals))
      (NP-2 (-NONE-:[1814..1814] *ICH*)))
    (VP (VBD:[1815..1819] were)
      (VP (VBN:[1820..1830] classified)
        (NP-1 (-NONE-:[1830..1830] *))
        (PP-CLR (IN:[1831..1833] as)
          (NP
            (NP (JJ:[1834..1840] strong) (NNS:[1841..1851] inhibitors))
            (PP (IN:[1853..1855] of)
              (NP (NN:[1856..1862] CYP2A6)))
            (PRN (-LRB-:[1863..1864] -LRB-)
              (S
                (NP-SBJ (-NONE-:[1864..1864] *))
                (VP (VBN:[1864..1871] defined)
                  (NP (-NONE-:[1871..1871] *))
                  (PP (IN:[1872..1874] by)
                    (NP-LGS
                      (NP (NN:[1875..1877] Ki))
                      (VP (SYM:[1878..1879] <)
                        (NP (CD:[1880..1883] 200) (NN:[1884..1890] microM)))))))
              (-RRB-:[1890..1891] -RRB-))))
        (::[1891..1892] :)
        (NP-2 (NN:[1893..1905] clotrimazole) (,:[1905..1906] ,)
              (NN:[1907..1929] diethyldithiocarbamate) (,:[1929..1930] ,)
              (NN:[1932..1943] ellipticine) (,:[1943..1944] ,)
              (NN:[1945..1957] ketoconazole) (,:[1957..1958] ,)
              (NN:[1959..1976] 8-methoxypsoralen) (,:[1976..1977] ,)
              (NN:[1978..1994] 4-methylpyrazole) (,:[1994..1995] ,)
              (NN:[1996..2006] metyrapone) (,:[2006..2007] ,)
              (NN:[2009..2019] miconazole) (,:[2019..2020] ,)
              (NN:[2021..2041] alpha-naphthoflavone) (,:[2041..2042] ,)
              (NN:[2043..2051] nicotine) (,:[2051..2052] ,)
              (NN:[2053..2066] p-nitrophenol) (,:[2066..2067] ,)
              (CC:[2068..2071] and) (NN:[2072..2087] tranylcypromine))))
    (.:[2087..2088] .)))

;sentence 11 Span:2090..2240
;The potency with which each chemical inhibited the 7-hydroxylation of
;coumarin  was independent of which sample of human liver microsomes was
;studied.
;[2118..2126]:substance:"chemical"
;[2160..2168]:substance:"coumarin"
(SENT
  (S
    (NP-SBJ
      (NP (DT:[2090..2093] The) (NN:[2094..2101] potency))
      (SBAR
        (WHPP-2 (IN:[2102..2106] with)
          (WHNP (WDT:[2107..2112] which)))
        (S
          (NP-SBJ (DT:[2113..2117] each) (NN:[2118..2126] chemical))
          (VP (VBD:[2127..2136] inhibited)
            (NP
              (NP (DT:[2137..2140] the) (CD:[2141..2142] 7)
                  (HYPH:[2142..2143] -) (NN:[2143..2156] hydroxylation))
              (PP (IN:[2157..2159] of)
                (NP (NN:[2160..2168] coumarin))))
            (PP-2 (-NONE-:[2168..2168] *T*))))))
    (VP (VBD:[2170..2173] was)
      (ADJP-PRD (JJ:[2174..2185] independent)
        (PP (IN:[2186..2188] of)
          (SBAR-NOM
            (WHNP-3
              (WHNP (WDT:[2189..2194] which) (NN:[2195..2201] sample))
              (PP (IN:[2202..2204] of)
                (NP (JJ:[2205..2210] human) (NN:[2211..2216] liver)
                    (NNS:[2217..2227] microsomes))))
            (S
              (NP-SBJ-3 (-NONE-:[2227..2227] *T*))
              (VP (VBD:[2228..2231] was)
                (VP (VBN:[2232..2239] studied)
                  (NP-1 (-NONE-:[2239..2239] *)))))))))
    (.:[2239..2240] .)))

;sentence 12 Span:2241..2454
;One of  the most potent inhibitors of coumarin 7-hydroxylase was
;8-methoxypsoralen  (methoxsalen), which was determined to be a
;mechanism-based inhibitor (suicide  substrate) of CYP2A6 (k(inactivation) 0.5
;min-1).
;[2265..2275]:substance:"inhibitors"
;[2279..2301]:cyp450:"coumarin 7-hydroxylase"
;[2306..2323]:substance:"8-methoxypsoralen"
;[2326..2337]:substance:"methoxsalen"
;[2385..2394]:substance:"inhibitor"
;[2405..2414]:substance:"substrate"
;[2419..2425]:cyp450:"CYP2A6"
;[2427..2442]:quantitative-name:"k(inactivation)"
;[2443..2446]:quantitative-value:"0.5"
;[2447..2452]:quantitative-units:"min-1"
(SENT
  (S
    (NP-SBJ
      (NP (CD:[2241..2244] One))
      (PP (IN:[2245..2247] of)
        (NP
          (NP (DT:[2249..2252] the)
            (ADJP (RBS:[2253..2257] most) (JJ:[2258..2264] potent))
            (NNS:[2265..2275] inhibitors))
          (PP (IN:[2276..2278] of)
            (NP (NN:[2279..2287] coumarin) (NN:[2288..2301] 7-hydroxylase))))))
    (VP (VBD:[2302..2305] was)
      (NP-PRD
        (NP
          (NP (NN:[2306..2323] 8-methoxypsoralen))
          (NP (-LRB-:[2325..2326] -LRB-) (NN:[2326..2337] methoxsalen)
              (-RRB-:[2337..2338] -RRB-)))
        (,:[2338..2339] ,)
        (SBAR
          (WHNP-1 (WDT:[2340..2345] which))
          (S
            (NP-SBJ-1 (-NONE-:[2345..2345] *T*))
            (VP (VBD:[2346..2349] was)
              (VP (VBN:[2350..2360] determined)
                (S
                  (NP-SBJ-1 (-NONE-:[2360..2360] *))
                  (VP (TO:[2361..2363] to)
                    (VP (VB:[2364..2366] be)
                      (NP-PRD
                        (NP (DT:[2367..2368] a)
                          (ADJP (NN:[2369..2378] mechanism)
                                (HYPH:[2378..2379] -) (VBN:[2379..2384] based))
                          (NN:[2385..2394] inhibitor)
                          (PRN (-LRB-:[2395..2396] -LRB-)
                            (NP (NN:[2396..2403] suicide)
                                (NN:[2405..2414] substrate))
                            (-RRB-:[2414..2415] -RRB-)))
                        (PP (IN:[2416..2418] of)
                          (NP (NN:[2419..2425] CYP2A6)
                            (PRN (-LRB-:[2426..2427] -LRB-)
                              (S
                                (NP-SBJ
                                        (NN:[2427..2442] k-LRB-inactivation-RRB-))
                                (NP-PRD (CD:[2443..2446] 0.5)
                                        (NN:[2447..2452] min-1)))
                              (-RRB-:[2452..2453] -RRB-))))))))))))))
    (.:[2453..2454] .)))

;sentence 13 Span:2455..2632
;With the exception of  8-methoxypsoralen, preincubation of human liver
;microsomes and NADPH with the  aforementioned inhibitors did not increase
;their ability to inhibit CYP2A6.
;[2478..2495]:substance:"8-methoxypsoralen"
;[2541..2546]:substance:"NADPH"
;[2572..2582]:substance:"inhibitors"
;[2625..2631]:cyp450:"CYP2A6"
(SENT
  (S
    (PP (IN:[2455..2459] With)
      (NP
        (NP (DT:[2460..2463] the) (NN:[2464..2473] exception))
        (PP (IN:[2474..2476] of)
          (NP (NN:[2478..2495] 8-methoxypsoralen)))))
    (,:[2495..2496] ,)
    (NP-SBJ
      (NP (NN:[2497..2510] preincubation))
      (PP (IN:[2511..2513] of)
        (NP
          (NP (JJ:[2514..2519] human) (NN:[2520..2525] liver)
              (NNS:[2526..2536] microsomes))
          (CC:[2537..2540] and)
          (NP (NN:[2541..2546] NADPH))))
      (PP (IN:[2547..2551] with)
        (NP (DT:[2552..2555] the) (JJ:[2557..2571] aforementioned)
            (NNS:[2572..2582] inhibitors))))
    (VP (VBD:[2583..2586] did) (RB:[2587..2590] not)
      (VP (VB:[2591..2599] increase)
        (NP (PRP$:[2600..2605] their) (NN:[2606..2613] ability)
          (S
            (NP-SBJ (-NONE-:[2613..2613] *))
            (VP (TO:[2614..2616] to)
              (VP (VB:[2617..2624] inhibit)
                (NP (NN:[2625..2631] CYP2A6))))))))
    (.:[2631..2632] .)))

;sentence 14 Span:2633..2722
;The  most potent competitive inhibitor of CYP2A6 was tranylcypromine (Ki =
;0.04  microM).
;[2662..2671]:substance:"inhibitor"
;[2675..2681]:cyp450:"CYP2A6"
;[2686..2701]:substance:"tranylcypromine"
;[2703..2705]:quantitative-name:"Ki"
;[2708..2712]:quantitative-value:"0.04"
;[2714..2720]:quantitative-units:"microM"
(SENT
  (S
    (NP-SBJ
      (NP (DT:[2633..2636] The)
        (ADJP (RBS:[2638..2642] most) (JJ:[2643..2649] potent))
        (JJ:[2650..2661] competitive) (NN:[2662..2671] inhibitor))
      (PP (IN:[2672..2674] of)
        (NP (NN:[2675..2681] CYP2A6))))
    (VP (VBD:[2682..2685] was)
      (NP-PRD (NN:[2686..2701] tranylcypromine)
        (PRN (-LRB-:[2702..2703] -LRB-)
          (S
            (NP-SBJ (NN:[2703..2705] Ki))
            (VP (SYM:[2706..2707] =)
              (NP (CD:[2708..2712] 0.04) (NN:[2714..2720] microM))))
          (-RRB-:[2720..2721] -RRB-))))
    (.:[2721..2722] .)))

;sentence 15 Span:2723..2921
;Several of the chemicals that strongly inhibited CYP2A6, such as 
;ketoconazole and tranylcypromine, are often used with the intention of 
;selectively inhibiting human P450 enzymes other than CYP2A6.
;[2738..2747]:substance:"chemicals"
;[2772..2778]:cyp450:"CYP2A6"
;[2789..2801]:substance:"ketoconazole"
;[2806..2821]:substance:"tranylcypromine"
;[2890..2902]:cyp450:"P450 enzymes"
;[2914..2920]:cyp450:"CYP2A6"
(SENT
  (S
    (NP-SBJ-2
      (NP
        (NP (JJ:[2723..2730] Several))
        (PP (IN:[2731..2733] of)
          (NP (DT:[2734..2737] the) (NNS:[2738..2747] chemicals))))
      (SBAR
        (WHNP-1 (WDT:[2748..2752] that))
        (S
          (NP-SBJ-1 (-NONE-:[2752..2752] *T*))
          (ADVP (RB:[2753..2761] strongly))
          (VP (VBD:[2762..2771] inhibited)
            (NP (NN:[2772..2778] CYP2A6)))))
      (,:[2778..2779] ,)
      (PP (JJ:[2780..2784] such) (IN:[2785..2787] as)
        (NP (NN:[2789..2801] ketoconazole) (CC:[2802..2805] and)
            (NN:[2806..2821] tranylcypromine))))
    (,:[2821..2822] ,)
    (VP (VBP:[2823..2826] are)
      (ADVP-TMP (RB:[2827..2832] often))
      (VP (VBN:[2833..2837] used)
        (NP-2 (-NONE-:[2837..2837] *))
        (PP (IN:[2838..2842] with)
          (NP
            (NP (DT:[2843..2846] the) (NN:[2847..2856] intention))
            (PP (IN:[2857..2859] of)
              (S-NOM
                (NP-SBJ (-NONE-:[2859..2859] *))
                (ADVP (RB:[2861..2872] selectively))
                (VP (VBG:[2873..2883] inhibiting)
                  (NP
                    (NP (JJ:[2884..2889] human)
                       (NN:[2890..2894] P450) (NNS:[2895..2902] enzymes))
                    (ADJP (JJ:[2903..2908] other)
                      (PP (IN:[2909..2913] than)
                        (NP (NN:[2914..2920] CYP2A6))))))))))))
    (.:[2920..2921] .)))

;sentence 16 Span:2922..3050
;The results of this  study underscore the need for a systematic evaluation of
;the specificity of  commonly used P450 inhibitors.
;[3034..3038]:cyp450:"P450"
;[3039..3049]:substance:"inhibitors"
(SENT
  (S
    (NP-SBJ
      (NP (DT:[2922..2925] The) (NNS:[2926..2933] results))
      (PP (IN:[2934..2936] of)
        (NP (DT:[2937..2941] this) (NN:[2943..2948] study))))
    (VP (VBP:[2949..2959] underscore)
      (NP
        (NP (DT:[2960..2963] the) (NN:[2964..2968] need))
        (PP (IN:[2969..2972] for)
          (NP
            (NP (DT:[2973..2974] a) (JJ:[2975..2985] systematic)
                (NN:[2986..2996] evaluation))
            (PP (IN:[2997..2999] of)
              (NP
                (NP (DT:[3000..3003] the) (NN:[3004..3015] specificity))
                (PP (IN:[3016..3018] of)
                  (NP
                    (ADJP (RB:[3020..3028] commonly) (VBN:[3029..3033] used))
                    (NN:[3034..3038] P450) (NNS:[3039..3049] inhibitors)))))))))
    (.:[3049..3050] .)))

;section 17 Span:3054..3097
;PMID: 9143352 [PubMed - indexed for MEDLINE
(SEC
  (FRAG (NNP:[3054..3058] PMID) (::[3058..3059] :) (CD:[3060..3067] 9143352)
        (-LRB-:[3068..3069] -LSB-) (NNP:[3069..3075] PubMed) (::[3076..3077] -)
        (VBN:[3078..3085] indexed) (IN:[3086..3089] for)
        (NNP:[3090..3097] MEDLINE)))
;ERROR_Orphan Text from EOF Tree File[3097..EOF] ]

(ORPH -RSB-)
